UK markets closed
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • FTSE 250

    23,608.79
    -221.39 (-0.93%)
     
  • AIM

    1,268.15
    -4.25 (-0.33%)
     
  • GBP/EUR

    1.1676
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.3680
    -0.0041 (-0.30%)
     
  • BTC-GBP

    30,528.12
    -1,650.16 (-5.13%)
     
  • CMC Crypto 200

    1,040.12
    -62.94 (-5.71%)
     
  • S&P 500

    4,449.21
    +0.23 (+0.01%)
     
  • DOW

    34,763.64
    -1.18 (-0.00%)
     
  • CRUDE OIL

    73.76
    +0.46 (+0.63%)
     
  • GOLD FUTURES

    1,751.20
    +1.40 (+0.08%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     
  • HANG SENG

    24,192.16
    -318.82 (-1.30%)
     
  • DAX

    15,531.75
    -112.22 (-0.72%)
     
  • CAC 40

    6,638.46
    -63.52 (-0.95%)
     

ICL or NVZMY: Which Is the Better Value Stock Right Now?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Israel Chemicals (ICL) or Novozymes AS (NVZMY). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.

Israel Chemicals has a Zacks Rank of #2 (Buy), while Novozymes AS has a Zacks Rank of #3 (Hold) right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ICL is likely seeing its earnings outlook improve to a greater extent. However, value investors will care about much more than just this.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

ICL currently has a forward P/E ratio of 17.45, while NVZMY has a forward P/E of 42.88. We also note that ICL has a PEG ratio of 0.76. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVZMY currently has a PEG ratio of 9.32.

Another notable valuation metric for ICL is its P/B ratio of 2.15. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, NVZMY has a P/B of 9.91.

These are just a few of the metrics contributing to ICL's Value grade of B and NVZMY's Value grade of D.

ICL sticks out from NVZMY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ICL is the better option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Israel Chemicals Shs (ICL) : Free Stock Analysis Report
 
Novozymes AS (NVZMY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting